Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir

Vivek K Kataria; Mezgebe Berhe; Uriel Sandkovsky

doi:10.1080/08998280.2022.2075676

Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir

Proc (Bayl Univ Med Cent). 2022 May 18;35(5):655-657. doi: 10.1080/08998280.2022.2075676. eCollection 2022.

Authors

Vivek K Kataria¹, Mezgebe Berhe², Uriel Sandkovsky²

Affiliations

¹ Department of Pharmacy, Baylor University Medical Center, Dallas, Texas.
² North Texas Infectious Disease Consultants, Baylor University Medical Center, Dallas, Texas.

Abstract

Evidence suggests that SARS-CoV-2 viral load is an independent predictor of disease severity and mortality. A 61-year-old woman presented with severe COVID-19 and was treated with casirivimab/imdevimab and remdesivir. Quantitative nasopharyngeal (NP) viral loads were trended throughout the treatment course. Baseline NP viral load was 25,860,901 copies/mL (7.4 log10). Casirivimab/imdevimab was administered, with subsequent reduction in NP viral load to 26,049 copies/mL (4.4 log10) on hospital day 4. A repeat NP viral load on day 7 was 13,113 copies/mL (4.1 log10). Despite uncertainty regarding correlation with reduction in viral load and outcomes, NP viral load may be considered when selecting treatment options and evaluating treatment response in hospitalized patients with early infection.

Keywords: COVID; anti-infectives; infectious diseases.

Publication types

Case Reports